Acute rhabdomyolysis

Rhabdomyolysis results from the rapid breakdown of skeletal muscle fibers, which leads to leakage of potentially toxic cellular contents into the systemic circulation. Acquired causes by direct injury to the sarcolemma are the most frequent. The inherited causes are: metabolic with failure of energy production, including mitochondrial fatty acid ß-oxidation defects, LPIN1 mutations, inborn errors of glycogenolysis and glycolysis, more rarely mitochondrial respiratory chain deficiency, purine defects and peroxysomalα-Methylacyl-CoA-racemase defect (AMACR); dystrophinopathies and myopathies; calcic causes with RYR1 mutations; inflammatory with myositis. Irrespective of the cause of rhabdomyolysis, the pathophysiologic events follow a common pathway, the ATP depletion leading to an increased intracellular calcium concentration and necrosis. Most episodes of rhabdomyolysis are triggered by an environmental stress, mostly fever. This condition is associated with two events, elevated temperature and high circulating levels of pro-inflammatory mediators such as cytokines and chemokines. We describe here an example of rhabdomyolysis related to high temperature, aldolase deficiency, in 3 siblings with episodic rhabdomyolysis without hemolytic anemia. Myoglobinuria was always triggered by febrile illnesses. We show that the underlying mechanism involves an exacerbation of aldolase A deficiency at high temperatures that affected myoblasts but not erythrocytes. Thermolability was enhanced in patient myoblasts compared to control. The aldolase A deficiency was rescued by arginine supplementation in vitro. Lipid droplets accumulated in patient myoblasts relative to control and this was increased by cytokines. Lipotoxicity may participate to myolysis. Our results expand the clinical spectrum of aldolase A deficiency to isolated temperature-dependent rhabdomyolysis, and suggest that thermolability may be tissue specific. We also propose a treatment for this severe disease. Some other diseases involved in rhabdomyolysis may implicate pro-inflammatory cytokines and may be proinflammatory diseases.

1. Sauret J.M., Marinides G., Wang G.K. Rhabdomyolysis. Am Fam Physician 2002;65(5):907– 12.

2. Brown C.V., Rhee P., Chan L. et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004;56(6):1191–6.

3. Alpers J.P., Jones L.K. Jr. Natural history of exertional rhabdomyolysis: a populationbased analysis. Muscle Nerve 2010;42(4): 487–91.

4. Perreault S., Birca A., Piper D., et al. Transient creatine phosphokinase elevations in children: a single-center experience. J Pediatr. 2011 Oct;159(4):682–5.

5. Mackay M.T., Kornberg A.J., Shield L.K. et al. Benign acute childhood myositis: laboratory and clinical features. Neurology 1999;53(9):2127–31.

6. Zutt R., van der Kooi A.J., Linthorst G.E. et al. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014;24(8):651–9.

7. Tein I., DiMauro S., DeVivo D.C. Recurrent childhood myoglobinuria. Adv Pediatr 1990;37:77–117.

8. Tonin P., Lewis P., Servidei S. et al. Metabolic causes of myoglobinuria. Ann Neurol 1990;27(2):181–5.

9. Berardo A., DiMauro S., Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010;10(2):118–26.

10. DiMauro S., Garone C., Naini A. Metabolic myopathies. Curr Rheumatol Rep 2010;12(5):386–93.

11. Laforêt P., Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 2010;20(11):693–700.

12. Zeharia A., Shaag A., Houtkooper R.H. et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008;83(4):489–94.

13. Michot C., Hubert L., Brivet M. et al. LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood. Hum Mutat 2010;31(7):E1564–73.

14. Michot C., Hubert L., Romero N.B. et al. Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis 2012;35(6):1119–28.

15. Kapina V., Sedel F., Truffert A. et al. Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency. Neurology 2010;75(14):1300–2.

16. Darras B.T., Friedman N.R. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000;22(2):87–97.

17. Quinlivan R., Jungbluth H. Myopathic causes of exercise intolerance with rhabdomyolysis. Dev Med Child Neurol 2012; 54(10):886–91.

18. Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.

19. Shapiro M.L., Baldea A., Luchette F.A. Rhabdomyolysis in the intensive care unit. J Intensive Care Med 2012;27(6):335–42.

20. Cervellin G., Comelli I., Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010;48(6):749–56.

21. Luck R.P., Verbin S. Rhabdomyolysis: a review of clinical presentation, etiology, diagnosis, and management. Pediatr Emerg Care 2008;24(4):262–8.

22. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science. 1993;259(5091):87–91.

23. Xu H., Barnes G.T., Yang Q. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112(12): 1821–30.

24. Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12):1796–808.

25. Molenaar J.P., Voermans N.C., van Hoeve B.J et al. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Intern Med J 2014; 44(8):819–20.

26. East C., Alivizatos P.A., Grundy S.M. et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318(1):47–8.

27. Santos J. Jr. Exertional rhabdomyolysis. Potentially life-threatening consequence of intense exercise. JAAPA 1999;12(7):46–9, 53–5.

28. Hopkins P.M. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000;85(1):118–28.

29. Späte U., Schulze P.C. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7(3):265–9.

30. Ostrowski K., Rohde T., Asp S. et al. Chemokines are elevated in plasma after strenuous exercise in humans. Eur J Appl Physiol 2001;84(3):244–5.

31. Chen X., Xun K., Chen L. et al. TNFalpha, a potent lipid metabolism regulator. Cell Biochem Funct 2009;27(7):407–16.

32. Feingold K.R., Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987;80(1):184–90.

33. Grunfeld C., Adi S., Soued M. et al. Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. Cancer Res 1990;50(14): 4233–8.

34. Vallerie S.N., Hotamisligil G.S. The role of JNK proteins in metabolism. Sci Transl Med 2010;2(60):60rv5.

35. Chen C.W., Lin J., Chu Y.W. iStable: offtheshelf predictor integration for predicting protein stability changes. BMC Bioinformatics 2013;14 Suppl 2:S5.

36. Yao D.C., Tolan D.R., Murray M.F. et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDO A(Arg303X/Cys338Tyr). Blood 2004;103(6):2401–3.

37. Michot C., Mamoune A., Vamecq J. et al. Combination of lipid metabolism alterations and their sensitivity to inflammatory cytokines in human lipin-1-deficient myoblasts. Biochim Biophys Acta 2013;1832(12):2103–14.

38. van Adel B.A., Tarnopolsky M.A. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009;10(3):97–121.

39. Kreuder J., Borkhardt A., Repp R. et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 1996;334(17):1100–4.

40. Miwa S., Fujii H., Tani K. et al. Two cases of red cell aldolase deficiency associated with hereditary hemolytic anemia in a Japanese family. Am J Hematol 1981;11(4):425–37.

41. Beutler E., Scott S., Bishop A. et al. Red cell aldolase deficiency and hemolytic anemia: a new syndrome. Trans Assoc Am Physicians 1973;86:154–66.

42. Kishi H., Mukai T., Hirono A. et al. Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci USA 1987;84(23):8623–7.

43. Pacheco P., Vieira-de-Abreu A., Gomes R.N. et al. Monocyte chemoattractant protein-1/CC chemokine ligand 2 controls microtubule-driven biogenesis and leukotriene B4-synthesizing function of macrophage lipid bodies elicited by innate immune response. J Immunol 2007;179(12):8500–8.

44. Gomes R.N., Figueiredo R.T., Bozza F.A. et al. Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/cc chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production. Shock 2006;26(5):457–63.

45. Beernink P.T., Tolan D.R. Subunit interface mutants of rabbit muscle aldolase form active dimers. Protein Sci 1994;3(9):1383–91.

46. Takahashi I., Takasaki Y., Hori K. Sitedirected mutagenesis of human aldolase isozymes: the role of Cys-72 and Cys-338 residues of aldolase A and of the carboxyterminal Tyr residues of aldolases A and B. J Biochem 1989;105(2):281–6.

47. Tsantes A.E., Bonovas S., Travlou A. et al. Redox imbalance, macrocytosis, and RBC homeostasis. Antioxid Redox Signal 2006;8 (7–8):1205–16.

48. Marinkovic D., Zhang X., Yalcin S. et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007;117(8):2133–44.

49. Matés J.M, Pérez-Gómez C., Olalla L. et al. Allergy to drugs: antioxidant enzymic activities, lipid peroxidation and protein oxidative damage in human blood. Cell Biochem Funct 2000;18(2):77–84.

50. Crawford J.H., Isbell T.S., Huang Z. et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006;107(2):566–74.

51. Berendse K., Ebberink M.S., Ijlst L. et al. Arginine improves peroxisome functioning in cells from patients with a mild peroxisome biogenesis disorder. Orphanet J Rare Dis 2013;8:138.

52. Roth S.D., Schüttrumpf J., Milanov P. et al. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. PLoS One 2012;7(9):e44505.

53. Senesi P., Luzi L., Montesano A. et al. Betaine supplement enhances skeletal muscle differentiation in murine myoblasts via IGF-1 signaling activation. J Transl Med 2013; 11:174.